185 related articles for article (PubMed ID: 36374143)
1. Immunohistochemical expression of p53, Ki67, α-SMA, CD44 and CD31 in different histological subtypes of basal cell carcinoma.
Cojocaru A; Bîrjovanu C; Ciurea AM; Niculescu D; Orzan OA; Ion A; Alexandru DO; Pirici I; Vîlcea EJ; Marinescu EA; Ciurea ME
Rom J Morphol Embryol; 2022; 63(2):383-393. PubMed ID: 36374143
[TBL] [Abstract][Full Text] [Related]
2. Expression of p53, D2-40 and α-smooth muscle actin in different histological subtypes of facial basal cell carcinoma.
Mercut R; Ciurea ME; Mărgăritescu C; Popescu SM; Crăitoiu MM; Cotoi OS; Voinescu DC
Rom J Morphol Embryol; 2014; 55(2):263-72. PubMed ID: 24969973
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53.
Abdelsayed RA; Guijarro-Rojas M; Ibrahim NA; Sangueza OP
J Cutan Pathol; 2000 Apr; 27(4):169-75. PubMed ID: 10774937
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas.
Pilloni L; Bianco P; Manieli C; Senes G; Coni P; Atzori L; Aste N; Faa G
Eur J Histochem; 2009; 53(2):113-6. PubMed ID: 19683985
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma.
Barrett TL; Smith KJ; Hodge JJ; Butler R; Hall FW; Skelton HG
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):430-7. PubMed ID: 9308559
[TBL] [Abstract][Full Text] [Related]
6. Expression of p16 Protein in Cutaneous Basal Cell Carcinoma: Still far from Being Clearly Understood.
Bartoš V
Acta Dermatovenerol Croat; 2020 Jul; 28(1):43-44. PubMed ID: 32650852
[TBL] [Abstract][Full Text] [Related]
7. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis.
Smith KJ; Williams J; Corbett D; Skelton H
Am J Surg Pathol; 2001 Apr; 25(4):464-71. PubMed ID: 11257620
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis.
Vidal D; Matías-Guiu X; Alomar A
Br J Dermatol; 2004 Sep; 151(3):656-62. PubMed ID: 15377354
[TBL] [Abstract][Full Text] [Related]
9. Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation.
Ionescu DN; Arida M; Jukic DM
Arch Pathol Lab Med; 2006 Jan; 130(1):45-51. PubMed ID: 16390237
[TBL] [Abstract][Full Text] [Related]
10. Expressions of p53, cyclinD1 and histopathological features in basal cell carcinomas.
Koseoglu RD; Sezer E; Eyibilen A; Aladag I; Etikan I
J Cutan Pathol; 2009 Sep; 36(9):958-65. PubMed ID: 19187116
[TBL] [Abstract][Full Text] [Related]
11. A Comparative Study of CD56 and Smooth Muscle Actin Expression in Basal and Squamous Cell Carcinomas.
Yirmibes S; Balaban Adim S
Am J Dermatopathol; 2023 Dec; 45(12):816-819. PubMed ID: 37982465
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical nuclear staining for p53, PCNA, Ki-67 and bcl-2 in different histologic variants of basal cell carcinoma.
Mateoiu C; Pirici A; Bogdan F
Rom J Morphol Embryol; 2011; 52(1 Suppl):315-9. PubMed ID: 21424069
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of p53 and Ki67 Expression Profiles in Basal Cell Carcinomas in a Usual and an Unusual Location.
Süngü N; Kiran MM; Tatli Doğan H; Kiliçarslan A; Karakök E; Akyol M
Turk Patoloji Derg; 2018; 34(2):165-170. PubMed ID: 29630084
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical staining for Ber-EP4, p53, proliferating cell nuclear antigen, Ki-67, bcl-2, CD34, and factor XIIIa in nevus sebaceus.
Barrett TL; Smith KJ; Williams J; Corner SW; Hodge JJ; Skelton HG
Mod Pathol; 1999 May; 12(5):450-5. PubMed ID: 10349981
[TBL] [Abstract][Full Text] [Related]
15. Comparison of PTCH1, COX-2, p53, and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk.
Khalesi M; Waterhouse M; Whiteman DC; Johns R; Rosendahl C; Hackett T; Pollak T; Kimlin MG; Hacker E; Neale RE;
Int J Dermatol; 2016 Oct; 55(10):1096-105. PubMed ID: 27126210
[TBL] [Abstract][Full Text] [Related]
16. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma.
Ansarin H; Daliri M; Soltani-Arabshahi R
Eur J Dermatol; 2006; 16(5):543-7. PubMed ID: 17101476
[TBL] [Abstract][Full Text] [Related]
18. A correlation of alpha-smooth muscle actin and invasion in micronodular basal cell carcinoma.
Christian MM; Moy RL; Wagner RF; Yen-Moore A
Dermatol Surg; 2001 May; 27(5):441-5. PubMed ID: 11359490
[TBL] [Abstract][Full Text] [Related]
19. Immunoexpression of p53 and COX-2 in basal cell carcinoma.
Enache AO; Stepan AE; Mărgăritescu C; Pătraşcu V; Ciurea RN; Simionescu CE; Camen A
Rom J Morphol Embryol; 2018; 59(4):1115-1120. PubMed ID: 30845292
[TBL] [Abstract][Full Text] [Related]
20. CD56 and smooth muscle actin immunoreactivity in basal cell carcinomas: Are they indicators of differentiation or do they hold a diagnostic use?
Yirmibeş S; Adım ŞB; Saraydaroğlu Ö
J Cutan Pathol; 2023 Jan; 50(1):56-61. PubMed ID: 36054407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
